Logo image of KALA

KALA BIO INC (KALA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KALA - US4831192020 - Common Stock

0.675 USD
+0.07 (+12.37%)
Last: 1/16/2026, 8:00:02 PM
0.645 USD
-0.03 (-4.44%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

1

KALA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. KALA may be in some trouble as it scores bad on both profitability and health. KALA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • KALA had negative earnings in the past year.
  • KALA had a negative operating cash flow in the past year.
  • KALA had negative earnings in each of the past 5 years.
  • KALA had a negative operating cash flow in each of the past 5 years.
KALA Yearly Net Income VS EBIT VS OCF VS FCFKALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • KALA has a Return On Assets of -74.28%. This is in the lower half of the industry: KALA underperforms 64.15% of its industry peers.
  • Looking at the Return On Equity, with a value of -627.91%, KALA is doing worse than 76.42% of the companies in the same industry.
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROIC N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
KALA Yearly ROA, ROE, ROICKALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KALA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALA Yearly Profit, Operating, Gross MarginsKALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

  • KALA has more shares outstanding than it did 1 year ago.
  • KALA has more shares outstanding than it did 5 years ago.
  • KALA has a better debt/assets ratio than last year.
KALA Yearly Shares OutstandingKALA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
KALA Yearly Total Debt VS Total AssetsKALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -21.52, we must say that KALA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -21.52, KALA is doing worse than 83.77% of the companies in the same industry.
  • A Debt/Equity ratio of 2.65 is on the high side and indicates that KALA has dependencies on debt financing.
  • KALA's Debt to Equity ratio of 2.65 is on the low side compared to the rest of the industry. KALA is outperformed by 79.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Altman-Z -21.52
ROIC/WACCN/A
WACCN/A
KALA Yearly LT Debt VS Equity VS FCFKALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • KALA has a Current Ratio of 1.99. This is a normal value and indicates that KALA is financially healthy and should not expect problems in meeting its short term obligations.
  • KALA has a worse Current ratio (1.99) than 76.04% of its industry peers.
  • KALA has a Quick Ratio of 1.99. This is a normal value and indicates that KALA is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.99, KALA is not doing good in the industry: 74.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
KALA Yearly Current Assets VS Current LiabilitesKALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.09% over the past year.
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 25.21% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALA Yearly Revenue VS EstimatesKALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2031 2032 50M 100M 150M
KALA Yearly EPS VS EstimatesKALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KALA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALA Price Earnings VS Forward Price EarningsKALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALA Per share dataKALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KALA's earnings are expected to grow with 25.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.5%
EPS Next 3Y25.21%

More info and screens

0

5. Dividend

5.1 Amount

  • KALA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KALA BIO INC

NASDAQ:KALA (1/16/2026, 8:00:02 PM)

After market: 0.645 -0.03 (-4.44%)

0.675

+0.07 (+12.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-19
Earnings (Next)03-30
Inst Owners37.02%
Inst Owner Change0.51%
Ins Owners2%
Ins Owner Change-6.25%
Market Cap5.54M
Revenue(TTM)N/A
Net Income(TTM)-35.84M
Analysts45.71
Price Target1.53 (126.67%)
Short Float %11.55%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.62%
Min EPS beat(2)1.58%
Max EPS beat(2)41.67%
EPS beat(4)4
Avg EPS beat(4)25.08%
Min EPS beat(4)1.58%
Max EPS beat(4)41.67%
EPS beat(8)7
Avg EPS beat(8)15.48%
EPS beat(12)7
Avg EPS beat(12)-2.76%
EPS beat(16)9
Avg EPS beat(16)-6.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-95.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-38.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -21.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)113.01%
Cap/Depr(5y)128.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.7%
OCF growth 3YN/A
OCF growth 5YN/A

KALA BIO INC / KALA FAQ

What is the fundamental rating for KALA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KALA.


What is the valuation status of KALA BIO INC (KALA) stock?

ChartMill assigns a valuation rating of 1 / 10 to KALA BIO INC (KALA). This can be considered as Overvalued.


How profitable is KALA BIO INC (KALA) stock?

KALA BIO INC (KALA) has a profitability rating of 0 / 10.


How financially healthy is KALA BIO INC?

The financial health rating of KALA BIO INC (KALA) is 1 / 10.